CYBN 250117 2.50C (CYBN250117C2500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

CYBN250117C2500

Watchlist

0.00
0.000.00%

15min DelayClose Jan 10 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Cybin Highlights 2024 Progress, Launches Phase 3 Study for CYB003 to Treat Major Depressive Disorder
Benzinga11minutes ago
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
Businesswire07:30 ET
Psychedelic Drug Developer Lykos Could Get Lifeline From Former Tesla Board Member
Seeking AlphaJan 10 13:27 ET
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
BusinesswireJan 9 17:00 ET
Express News | Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including Cyb003 12-Month Efficacy Results
ReutersDec 10, 2024 07:30 ET
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
BusinesswireDec 10, 2024 07:30 ET

Comments

Jaguar8

1 hour ago

NEWS

$Cybin (CYBN.US)$
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
Monday, 13th January at 7:30 am
- Announced positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder ("MDD") -
- Initiated PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of MDD –
- Received U.S. Food and Drug Administration ("FDA") Breakthrough Therapy Designation ("BTD") for CYB003 for the Adjunc...

Jaguar8

Dec 10, 2024 06:44

NEWS

$Cybin (CYBN.US)$
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
Tuesday, 10th December at 7:30 am
- Poster presentations highlight clinical data across Cybin's CYB003 deuterated psilocin and DMT programs -
Cybin Inc. (NYSE: CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new...

Trytosaveabit

Dec 4, 2024 13:05

Update! Cybin gettin serious!

$Cybin (CYBN.US)$PR Newswire· 2 mins ago
PHOENIXVILLE, Pa., Dec. 4, 2024 /PRNewswire/ -- Facet Life Sciences, a leader in US regulatory strategy and product development solutions for the life sciences industry, has been named as the US regulatory partner for Cybin Inc. ("Cybin"), a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative treatment options to address the large unmet need for people ...

Mr Trecherous

Nov 25, 2024 20:06

Get Healthy 💪🏼 🥑 🥥 🍄 🐮

$Trump Media & Technology (DJT.US)$ $Pfizer (PFE.US)$ $McDonald's (MCD.US)$ $Tesla (TSLA.US)$ $AMC Entertainment (AMC.US)$ $Cybin (CYBN.US)$

Moo Humor

EZ_money

Nov 21, 2024 10:30

$Cybin (CYBN.US)$ buying more now 🖕